Barclays’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.5M | Sell |
160,100
-2,475,300
| -94% | -$65.9M | ﹤0.01% | 1883 |
|
|
2025
Q4 | $65.6M | Buy |
2,635,400
+2,350,300
| +824% | +$59.3M | 0.02% | 656 |
|
|
2025
Q3 | $7.26M | Sell |
285,100
-2,949,800
| -91% | -$72.8M | ﹤0.01% | 1923 |
|
|
2025
Q2 | $78.4M | Sell |
3,234,900
-3,221,800
| -50% | -$75.1M | 0.02% | 551 |
|
|
2025
Q1 | $164M | Buy |
6,456,700
+4,131,400
| +178% | +$108M | 0.05% | 293 |
|
|
2024
Q4 | $61.7M | Buy |
2,325,300
+1,522,000
| +189% | +$41.3M | 0.02% | 583 |
|
|
2024
Q3 | $23.2M | Buy |
803,300
+628,300
| +359% | +$18.3M | 0.01% | 987 |
|
|
2024
Q2 | $4.9M | Buy |
175,000
+100,000
| +133% | +$2.75M | ﹤0.01% | 1551 |
|
|
2024
Q1 | $2.08M | Sell |
75,000
-150,000
| -67% | -$4.16M | ﹤0.01% | 2540 |
|
|
2023
Q4 | $6.48M | Buy |
+225,000
| New | +$6.8M | ﹤0.01% | 1878 |
|
|
2023
Q3 | – | Sell |
-247,200
| Closed | -$9.07M | – | 4676 |
|
|
2023
Q2 | $9.07M | Sell |
247,200
-588,600
| -70% | -$22.9M | 0.01% | 1030 |
|
|
2023
Q1 | $34.1M | Buy |
835,800
+49,000
| +6% | +$2.12M | 0.02% | 625 |
|
|
2022
Q4 | $40.3M | Buy |
786,800
+481,600
| +158% | +$23.1M | 0.02% | 583 |
|
|
2022
Q3 | $13.4M | Sell |
305,200
-169,200
| -36% | -$8.22M | 0.01% | 753 |
|
|
2022
Q2 | $24.9M | Buy |
+474,400
| New | +$24.2M | 0.02% | 626 |
|
|
2022
Q1 | – | Sell |
-1,178,700
| Closed | -$69.6M | – | 5460 |
|
|
2021
Q4 | $69.6M | Buy |
1,178,700
+515,500
| +78% | +$25.5M | 0.03% | 461 |
|
|
2021
Q3 | $28.5M | Sell |
663,200
-376,000
| -36% | -$16.7M | 0.01% | 752 |
|
|
2021
Q2 | $40.7M | Buy |
1,039,200
+582,800
| +128% | +$22.7M | 0.02% | 595 |
|
|
2021
Q1 | $16.5M | Sell |
456,400
-481,300
| -51% | -$17.1M | 0.01% | 868 |
|
|
2020
Q4 | $34.5M | Sell |
937,700
-65,497
| -7% | -$2.4M | 0.02% | 578 |
|
|
2020
Q3 | $34.9M | Buy |
1,003,197
+55,546
| +6% | +$1.95M | 0.02% | 504 |
|
|
2020
Q2 | $29.4M | Sell |
947,651
-141,658
| -13% | -$4.81M | 0.02% | 492 |
|
|
2020
Q1 | $33.7M | Sell |
1,089,309
-164,213
| -13% | -$5.6M | 0.03% | 439 |
|
|
2019
Q4 | $46.6M | Buy |
1,253,522
+347,187
| +38% | +$12.4M | 0.03% | 535 |
|
|
2019
Q3 | $30.9M | Buy |
906,335
+493,167
| +119% | +$17.9M | 0.02% | 655 |
|
|
2019
Q2 | $17M | Sell |
413,168
-65,453
| -14% | -$2.6M | 0.01% | 1022 |
|
|
2019
Q1 | $19.3M | Sell |
478,621
-549,345
| -53% | -$22M | 0.01% | 877 |
|
|
2018
Q4 | $42.6M | Buy |
1,027,966
+73,569
| +8% | +$3.05M | 0.03% | 433 |
|
|
2018
Q3 | $39.9M | Sell |
954,397
-121,737
| -11% | -$4.69M | 0.03% | 510 |
|
|
2018
Q2 | $37M | Sell |
1,076,134
-103,608
| -9% | -$3.54M | 0.03% | 472 |
|
|
2018
Q1 | $39.7M | Buy |
1,179,742
+801,778
| +212% | +$27.6M | 0.03% | 518 |
|
|
2017
Q4 | $13M | Sell |
377,964
-90,328
| -19% | -$3.08M | 0.01% | 1050 |
|
|
2017
Q3 | $15.9M | Sell |
468,292
-94,966
| -17% | -$3.05M | 0.02% | 768 |
|
|
2017
Q2 | $17.9M | Sell |
563,258
-91,171
| -14% | -$2.88M | 0.02% | 660 |
|
|
2017
Q1 | $21.2M | Sell |
654,429
-1,219,899
| -65% | -$38.5M | 0.02% | 536 |
|
|
2016
Q4 | $57.8M | Sell |
1,874,328
-178,864
| -9% | -$5.46M | 0.06% | 243 |
|
|
2016
Q3 | $66M | Buy |
2,053,192
+521,730
| +34% | +$17.4M | 0.07% | 199 |
|
|
2016
Q2 | $51.2M | Sell |
1,531,462
-1,939,149
| -56% | -$61.9M | 0.07% | 247 |
|
|
2016
Q1 | $95.5M | Sell |
3,470,611
-330,851
| -9% | -$9.45M | 0.15% | 117 |
|
|
2015
Q4 | $115M | Buy |
3,801,462
+734,849
| +24% | +$23.1M | 0.14% | 123 |
|
|
2015
Q3 | $90.2M | Buy |
3,066,613
+952,816
| +45% | +$30.6M | 0.11% | 159 |
|
|
2015
Q2 | $66.2M | Sell |
2,113,797
-1,393,072
| -40% | -$45.4M | 0.07% | 223 |
|
|
2015
Q1 | $113M | Buy |
3,506,869
+225,556
| +7% | +$7.17M | 0.13% | 136 |
|
|
2014
Q4 | $96.5M | Buy |
3,281,313
+703,756
| +27% | +$20.2M | 0.09% | 173 |
|
|
2014
Q3 | $70.9M | Sell |
2,577,557
-129,220
| -5% | -$3.63M | 0.07% | 235 |
|
|
2014
Q2 | $74.5M | Buy |
2,706,777
+1,555,387
| +135% | +$44.3M | 0.08% | 200 |
|
|
2014
Q1 | $35M | Sell |
1,151,390
-659,070
| -36% | -$19.7M | 0.04% | 422 |
|
|
2013
Q4 | $51.5M | Buy |
1,810,460
+355,084
| +24% | +$10.3M | 0.05% | 337 |
|
|
2013
Q3 | $38.7M | Sell |
1,455,376
-12,331,787
| -89% | -$336M | 0.05% | 375 |
|
|
2013
Q2 | $366M | Buy |
+13,787,163
| New | +$381M | 0.46% | 23 |
|
Other funds holding PFE
VCM
VPM
Barclays's PFE Position: Q1 2026 in Review
Barclays reduced its Pfizer (PFE) stake by 19% in Q1 2026, selling an estimated $91.7M and leaving 14,689,187 shares worth $412M. The position accounts for 0.1% of the portfolio, ranked #150.
Barclays first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $892M in Q4 2021. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Barclays held 14,689,187 shares of Pfizer worth $412M as of Q1 2026.
- Barclays sold 3,444,802 Pfizer shares in Q1 2026, an estimated $91.7M.
- Pfizer made up 0.1% of Barclays's portfolio in Q1 2026, its #150 holding.
- Barclays first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Barclays's Pfizer position peaked at $892M in Q4 2021.
- 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.